Search - tctmd.com

Displaying 101 - 120 of 240

Sort: Relevancy | Date

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

Presentation TCT 2013

Use of Clopidogrel with or without Aspirin in Patients Taking Oral Anticoagulant Therapy and Undergoing Percutaneous Coronary Intervention: an Open-Label, Randomized, Controlled...

Presenter: Freek Verheugt

October 31, 2013

Presentation TCT 2013

TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use

Presenter: E. Magnus Ohman

October 31, 2013

Presentation TCT 2013

The DAPT Duration Dilemma: Recent Trials and Reasonable Guidelines for Clinical Practice

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

The Conundrum of Switching DAPT

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

Presenter: Roxana Mehran

October 31, 2013

Presentation TCT 2013

Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art

Presenter: E. Magnus Ohman

October 31, 2013

Presentation TCT 2013

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Presenter: Harvey White

October 31, 2013

Presentation TCT 2013

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Presenter: Kurt Huber

October 31, 2013

Presentation TCT 2013

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Presenter: Michelle O'Donoghue

October 31, 2013

Presentation TCT 2013

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Presenter: Masato Nakamura

October 31, 2013

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Presenter: Paul Gurbel

October 31, 2013

Presentation TCT 2013

Platelet Function and Genetic Testing are Currently Worthless

Presenter: Daniel Simon

October 31, 2013

Presentation TCT 2013

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Presenter: Peter Wenaweser

October 31, 2013

Presentation TCT 2013

Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year!

Presenter: Edoardo Camenzind

October 31, 2013

Presentation TCT 2013

New Insights Into High Platelet Reactivity and the Existence of a Therapeutic Window: ADAPT-DES 2-Year Results

Presenter: Ajay Kirtane

October 31, 2013

Presentation TCT 2013

Mortality Trumps All: Ticagrelor for (Nearly) All!

Presenter: Michel Le May

October 31, 2013

Presentation TCT 2013

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Presenter: Bernard Chevalier

October 31, 2013

Advertisement

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

Use of Clopidogrel with or without Aspirin in Patients Taking Oral Anticoagulant Therapy and Undergoing Percutaneous Coronary Intervention: an Open-Label, Randomized, Controlled...

TRILOGY-ACS Recap and Emerging Data: Implications for Current Prasugrel Use

The DAPT Duration Dilemma: Recent Trials and Reasonable Guidelines for Clinical Practice

The Conundrum of Switching DAPT

Shorter Is Better: New Insights From OPTIMIZE, PARIS, and Other Studies

Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Prasugrel Rules: Simplest Second-Generation Agent with Fewest Side Effects!

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Platelet Function and Genetic Testing are Currently Worthless

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year!

New Insights Into High Platelet Reactivity and the Existence of a Therapeutic Window: ADAPT-DES 2-Year Results

Mortality Trumps All: Ticagrelor for (Nearly) All!

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content